FASTinov

Founded in 2013 in Porto, Portugal, FASTinov is dedicated to the development of advanced antimicrobial susceptibility testing solutions.450 mn from Armilar Venture Partners and Bynd Venture Capital.FASTinov specializes in the development of ultra-rapid antimicrobial susceptibility testing (AST) solutions utilizing patented flow cytometry technology. The company's flagship product, the FASTinov AST kit, enables healthcare providers to receive antibiograms in under two hours, significantly faster than conventional methods which typically require 24-48 hours. This rapid testing is particularly vital for managing bloodstream infections caused by both Gram-positive and Gram-negative bacteria, facilitating timely antibiotic treatment decisions. The AST kit is complemented by the bioFAST software, which processes flow cytometry data to generate detailed susceptibility reports.FASTinov's revenue structure is primarily based on direct sales of its AST kits and associated software to healthcare institutions and laboratories. The company operates a B2B model, engaging directly with medical facilities that require rapid and reliable antimicrobial susceptibility testing solutions. Transactions typically involve the purchase of FASTinov AST kits, which are priced to reflect the advanced technology and quick turnaround provided. The bioFAST software is often bundled with the test kits, enhancing the overall value proposition for clients. Plans include the development of new testing products that are designed to further streamline the diagnostic process. Additionally, the company aims to penetrate new geographical markets beyond its current focus in Portugal and Spain, with targeted expansion efforts in broader European regions by the end of 2023. This growth strategy is aimed at meeting the increasing demand for rapid diagnostic solutions in the healthcare sector.

1. Seed

   Sep 29, 2019

   Amount

   $0.5M

   Investors

   Locked